References
- Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011;2011:498–505.
- Fujimura K, Ebinuma H, Fukamachi I, et al. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma. Clin Chim Acta 2014;430: 48–54.
- Sakai S, Nakaseko C, Takeuchi M, et al. Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. Clin Chim Acta 2012;413:1542–1548.
- Kawaguchi T, Ohwada C, Takeuchi M, et al. LR11: a novel biomarker identified in follicular lymphoma. Br J Haematol 2013; 163:277–280.
- Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 2013;48: 452–458.
- Carbone A, Gloghini A, Kwong YL, et al. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 2014;93:1263–1277.
- Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol 2014;25:2124–2133.
- Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
- Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123: 837–842.
- Zhu Y, Bujo H, Yamazaki H, et al. LR11, an LDL receptor gene family member, is a novel regulator of smooth muscle cell migration. Circ Res 2004;94:752–758.
- Yebra M, Goretzki L, Pfeifer M, et al. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 1999;250:231–240.
- Heiss MM, Simon EH, Beyer BC, et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002;20:2005–2016.
- Nishii K, Nakaseko C, Jiang M, et al. The soluble form of LR11 protein is a regulator of hypoxia-induced, urokinase-type plasminogen activator receptor (uPAR)-mediated adhesion of immature hematological cells. J Biol Chem 2013;288:11877–11886.
- Shimizu N, Nakaseko C, Jiang M, et al. G-CSF induces the release of the soluble form of LR11, a regulator of myeloid cell mobilization in bone marrow. Ann Hematol 2014;93:1111–1122.
- Tsukamoto S, Takeuchi M, Kawaguchi T, et al. Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in leukocytes. Exp Mol Med 2014;46:e89.